Skip to main content

Table 5 Indication of denosumab for GCTBa in 24 institutions

From: Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study

Indications of denosumab

No. of institutions (%)


21 (88%)

Difficult to joint preservation

17 (71%)

Expanding to soft tissue

11 (46%)

Adjusting the time of operation

7 (29%)

Perioperative use with curettage

6 (25%)

No experience of denosumab use

3 (13%)

  1. aGCTB, giant cell tumor of bone; some of the replies by responded institutions are overlapped